Clinical Trial Update: Secukinumab in Tumor Necrosis Factor (TNF) - Inadequate Response (IR) Psoriasis Participants. [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial update on secukinumab in psoriasis patients with inadequate response to TNF inhibitors completed in 2019 with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-03-18